About Recursion
Recursion (NASDAQ: RXRX) is a clinical-stage TechBio company that decodes biology to radically improve lives. It advances a portfolio of investigational medicines across oncology, rare disease, neuroscience, and immunology, enabled by the Recursion OS — an AI-native, end-to-end drug discovery and development platform integrating biology, chemistry, and clinical development into a unified intelligence system. The platform leverages proprietary multimodal data, purpose-built AI models, and automated laboratories to translate complex science into medicines faster and at scale.
Company details
Funding
Total raised
$452M
Last stage
Public
Investors
Founders
Dean Li
Co-founder of Recursion from his lab at the University of Utah. Current President of Merck Research Labs. Previously VP of Translational Medicine at Merck. Served as H.A. & Edna Benning Professor of Medicine and Cardiology and vice-dean of research at University of Utah Health Science Center.
Chris Gibson
Developed the technology and approach that seeded Recursion during his MD/PhD work at the University of Utah. Left medical school to build Recursion. Graduate of Rice University with degrees in bioengineering and management. Previously served as CEO.
LinkedInBlake Borgeson
Co-founded Recursion in 2013 alongside Christopher Gibson and Dean Li.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.